De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Revvity Beheer

Beheer criteriumcontroles 3/4

De CEO Revvity's is Prahlad Singh, benoemd in Jan2019, heeft een ambtstermijn van 5.75 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 9.13M, bestaande uit 11.9% salaris en 88.1% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.1% van de aandelen van het bedrijf, ter waarde € 14.70M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 5.3 jaar en 6.1 jaar.

Belangrijke informatie

Prahlad Singh

Algemeen directeur

US$9.1m

Totale compensatie

Percentage CEO-salaris	11.9%
Dienstverband CEO	5.8yrs
Eigendom CEO	0.1%
Management gemiddelde ambtstermijn	5.3yrs
Gemiddelde ambtstermijn bestuur	6.1yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Prahlad Singh's beloning veranderd ten opzichte van Revvity's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$197m
Mar 31 2024	n/a	n/a	US$183m
Dec 31 2023	US$9m	US$1m	US$180m
Oct 01 2023	n/a	n/a	US$213m
Jul 02 2023	n/a	n/a	US$250m
Apr 02 2023	n/a	n/a	US$353m
Jan 01 2023	US$11m	US$1m	US$513m
Oct 02 2022	n/a	n/a	US$599m
Jul 03 2022	n/a	n/a	US$637m
Apr 03 2022	n/a	n/a	US$694m
Jan 02 2022	US$10m	US$1m	US$889m
Oct 03 2021	n/a	n/a	US$1b
Jul 04 2021	n/a	n/a	US$1b
Apr 04 2021	n/a	n/a	US$1b
Jan 03 2021	US$9m	US$900k	US$631m
Oct 04 2020	n/a	n/a	US$412m
Jul 05 2020	n/a	n/a	US$294m
Apr 05 2020	n/a	n/a	US$226m
Dec 29 2019	US$4m	US$645k	US$228m
Sep 29 2019	n/a	n/a	US$235m
Jun 30 2019	n/a	n/a	US$251m
Mar 31 2019	n/a	n/a	US$247m
Dec 30 2018	US$2m	US$517k	US$237m
Sep 30 2018	n/a	n/a	US$128m
Jul 01 2018	n/a	n/a	US$149m
Apr 01 2018	n/a	n/a	US$147m
Dec 31 2017	US$2m	US$464k	US$157m

Compensatie versus markt: De totale vergoeding ($USD 9.13M ) Prahlad } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 5.31M ).

Compensatie versus inkomsten: De vergoeding van Prahlad is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Prahlad Singh (59 yo)

5.8yrs

Tenure

US$9,130,624

Compensatie

Dr. Prahlad R. Singh, PhD has been the Chief Executive Officer of Revvity, Inc. (formerly known as PerkinElmer, Inc.) since December 30, 2019. Dr. Singh served as the Chairman of the Supervisory Board at E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Prahlad Singh	CEO, President & Director	5.8yrs	US$9.13m	0.10% $ 14.4m
Maxwell Krakowiak	Senior VP & CFO	2.2yrs	US$2.75m	0.0026% $ 362.2k
Tajinder Vohra	Senior Vice President of Global Operations	6.8yrs	US$1.76m	0.021% $ 2.9m
Joel Goldberg	Senior VP of Administration	16.3yrs	US$2.64m	0.079% $ 11.0m
Miriame Victor	Senior VP & Chief Commercial Officer	3.8yrs	US$1.70m	0.0072% $ 997.4k
Andrew Okun	VP, Chief Accounting Officer & Treasurer	13.5yrs	geen gegevens	0.00053% $ 73.8k
Bryan Kipp	Senior Vice President of Technology & Licensing	less than a year	geen gegevens	geen gegevens
Madhuri Hegde	Senior VP & Chief Scientific Officer	no data	geen gegevens	geen gegevens
Stephen Willoughby	Senior VP of Investor Relations & Head of ESG	no data	geen gegevens	geen gegevens
Magali Four	Senior VP and Chief People & Culture Officer	no data	geen gegevens	geen gegevens
Robert Friel	Advisor	4.8yrs	US$16.48m	geen gegevens
Kevin Willoe	Senior VP & GM of Revvity Signals Software	no data	geen gegevens	geen gegevens

5.3yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van PKN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 5.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Prahlad Singh	CEO, President & Director	5.2yrs	US$9.13m	0.10% $ 14.4m
Alexis Michas	Independent Non-Executive Chairman	23.8yrs	US$465.08k	0.054% $ 7.5m
Peter Barrett	Independent Director	12.7yrs	US$310.07k	0.018% $ 2.6m
Franklin Witney	Independent Director	8.3yrs	US$295.07k	0.014% $ 2.0m
Samuel Chapin	Independent Director	8yrs	US$315.07k	0.014% $ 1.9m
Sophie Vandebroek	Independent Director	less than a year	geen gegevens	0.0014% $ 192.2k
Pascale Witz	Independent Director	7yrs	US$290.07k	0.0084% $ 1.2m
Michel Vounatsos	Independent Director	4.6yrs	US$305.07k	0.0067% $ 938.9k
Michael Klobuchar	Independent Director	less than a year	geen gegevens	0.0014% $ 192.2k
Michelle McMurry-Heath	Independent Director	2.3yrs	US$290.07k	0.0032% $ 452.7k

6.1yrs

Gemiddelde duur

62yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van PKN wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).

Revvity Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Insufficient new directors

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

PerkinElmer, Inc. Elects Michelle McMurry-Heath to its Board of Directors

Recent updates

Second quarter 2024 earnings released: EPS: US$0.59 (vs US$0.47 in 2Q 2023)

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity Board Declares Quarterly Dividend, Payable on November 8, 2024

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q2, 2024 Results on Jul 29, 2024

First quarter 2024 earnings released: EPS: US$0.23 (vs US$0.20 in 1Q 2023)

Revvity, Inc. Updates Earnings Guidance for the Full Year 2024

Dividend of US$0.07 announced

Revvity, Inc. Declares Quarterly Dividend, Payable on August 9, 2024

Revvity Unveils A New Era of Automated Tuberculosis Testing

Upcoming dividend of US$0.07 per share

Revvity, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Revvity, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Revvity Signals Software Introduces Signals ChemDraw Offering to Set New Standard for Cloud-Native Chemistry Communication

Revvity, Inc. Introduces New Workflow to Accelerate Newborn Sequencing Research

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity Signals Software Unveils Signals Clinical Solution to Accelerate Critical Clinical Trial Insights and Data-Driven Decisions

New minor risk - Earnings quality

Revvity Showcases Cutting-Edge Solutions at SLAS2024

Full year 2023 earnings released: EPS: US$1.44 (vs US$4.06 in FY 2022)

Revvity, Inc. Provides Revenue Guidance for the Full Year of 2024

Dividend of US$0.07 announced

Revvity, Inc., Annual General Meeting, Apr 23, 2024

Revvity, Inc. Announces Board Elections, Effective February 1, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q4, 2023 Results on Feb 01, 2024

Revvity, Inc. Provides Revenue Guidance for the Fourth Quarter 2023

Investor sentiment improves as stock rises 15%

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

Revvity, Inc. Launches EONIS Q System, Enabling Faster, Simplified Newborn Screening for SMA and SCID

New major risk - Revenue and earnings growth

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings released: EPS: US$0.26 (vs US$0.55 in 3Q 2022)

Revvity Board Declares Quarterly Dividend, Payable on February 9, 2024

Upcoming dividend of US$0.07 per share at 0.3% yield

Revvity, Inc. to Report Q3, 2023 Results on Oct 30, 2023

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Revvity, Inc. Unveils Several Next-Generation Preclinical Imaging Technologies to Help Scientists Drive Breakthrough Discoveries

New minor risk - Earnings quality

Revvity, Inc. Provides Earnings Guidance for the Full Year 2023

Second quarter 2023 earnings released: EPS: US$0.47 (vs US$1.33 in 2Q 2022)

Revvity Declares Quarterly Dividend, Payable on November 10, 2023

Revvity, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Upcoming dividend of US$0.07 per share at 0.2% yield

Honeycomb Biotechnologies and Revvity Launch New Solutions to Expand the Frontiers of Single Cell Research

Revvity, Inc. Launches First Scientific SaaS Platform to Accelerate Drug and Materials Development

First quarter 2023 earnings released: EPS: US$0.20 (vs US$1.40 in 1Q 2022)

Revvity, Inc. (NYSE:PKI) announces an Equity Buyback for $600 million worth of its shares.

Upcoming dividend of US$0.07 per share at 0.2% yield

Insufficient new directors

PerkinElmer, Inc. Provides Earnings Guidance for the Full Year of 2023

Full year 2022 earnings released: EPS: US$4.13 (vs US$8.12 in FY 2021)

PerkinElmer, Inc. Declares Regular Quarterly Dividend, Payable on May 12, 2023

Now 22% undervalued after recent price drop

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. to Report Q4, 2022 Results on Feb 14, 2023

Now 24% undervalued after recent price drop

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$0.94 in 3Q 2021)

PerkinElmer Announces its EONIS SCID-SMA Kit is First to Receive Marketing Authorization by U.S. FDA for SMA Screening in Newborns

Third quarter 2022 earnings released: EPS: US$0.55 (vs US$1.12 in 3Q 2021)

PerkinElmer, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year of 2022

PerkinElmer, Inc. Declares a Regular Quarterly Dividend, Payable on February 10, 2023

PerkinElmer, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Upcoming dividend of US$0.07 per share

PerkinElmer, Inc. Unveils Cell Analysis Solution to Streamline Cell and Gene Therapy Research and Manufacturing

Perkinelmer’S Oxford Immunotec Receives U.S. Fda Approval for T-Cell Select to Automate Clinically Superior Tuberculosis Detection

PerkinElmer, Inc. Announces Appointment of Maxwell Krakowiak as Senior Vice President, Effective September 6, 2022

Second quarter 2022 earnings released: EPS: US$1.42 (vs US$2.20 in 2Q 2021)

New Mountain Capital, L.L.C. entered into a definitive agreement with the intention to acquire Applied, Food and Enterprise Services businesses of PerkinElmer, Inc. (NYSE:PKI) for $2.5 billion.